Evidence map›Paper›PMID 40830651›Full record

ArticleScientific reports2025

Nasal Aβ42 mirrors brain amyloid dynamics and cognitive decline across the Alzheimer's disease continuum.

Da Hae Jung, Gowoon Son, Sheng Min Wang, Seung-Jun Yoo, Ali Jahanshahi, Hyun Kook Lim, Cheil Moon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Da Hae JungDepartment of Brain Sciences, Graduate School, Daegu Gyeongbuk Institute of Science and Technology (DGIST), 333 Techno Jungang-daero, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Gowoon SonDepartment of Brain Sciences, Graduate School, Daegu Gyeongbuk Institute of Science and Technology (DGIST), 333 Techno Jungang-daero, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea.
Sheng Min WangDepartment of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, Republic of Korea.
Seung-Jun YooDepartment of Life Science, College of Natural Sciences, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.
Ali JahanshahiDepartment of Neurosurgery, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
Hyun Kook LimDepartment of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, Republic of Korea. drblues@catholic.ac.kr.
Cheil MoonDepartment of Brain Sciences, Graduate School, Daegu Gyeongbuk Institute of Science and Technology (DGIST), 333 Techno Jungang-daero, Hyeonpung-eup, Dalseong-gun, Daegu, 42988, Republic of Korea. cmoon@dgist.ac.kr.

Funding

Korea Health Industry Development Institute HI18C0154National Research Foundation of Korea RS-2020-NR049577
6 · The paper itself

Abstract

Early, non-invasive assessment of Alzheimer's disease (AD) progression remains a key challenge. This study evaluated whether nasal amyloid-β42 (Aβ42) levels reflect brain amyloid dynamics and cognitive decline. Nasal discharge from 161 individuals, ranging from cognitively unimpaired to AD dementia, was analyzed using ELISA, alongside neuropsychological assessments and amyloid PET imaging. Moderate nasal Aβ42 levels (9.53-11.10 pg/mL) were positively associated with PET amyloid burden and cognitive decline, identifying a critical transitional disease stage. Conversely, the highest Aβ42 levels showed weaker correlations, suggesting a non-linear progression. The pattern of nasal Aβ42 mirrored brain amyloid accumulation, which peaks and stabilizes in later disease stages. These findings highlight nasal Aβ42 as a promising, scalable biomarker for tracking AD pathology and offer the first evidence linking it with brain amyloid PET. This supports its potential use in both clinical and longitudinal research settings.

Indexed as

Alzheimer DiseaseAmyloidAmyloid beta-PeptidesBrainCognitive DysfunctionPeptide FragmentsAgedAged, 80 and overBiomarkersDisease ProgressionFemaleHumansMaleMiddle AgedPositron-Emission TomographyAmyloidAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide FragmentsAlzheimer’s diseaseAmyloid-β 42Brain amyloidosisNasal dischargeNon-invasive monitoring

Identifiers

PMID40830651
PMCPMC12365175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.